Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

BETHESDA, Md., March 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included below for the fiscal year 2006 consists of Micromet AG's historical financial results for the period of January 1, 2006 to May 5, 2006 without the inclusion of the financial results of CancerVax, and the combined results of the two companies thereafter.

Summary of Recent Events:

-- Micromet published data on its BiTE(R) antibody MT103 at the annual

meeting of the American Society of Hematology in December, showing that

MT103 induces dose-dependent objective complete and partial responses

in late stage lymphoma patients. The BiTE antibody could also clear the

bone marrow and other infiltrated organs from tumor cells. Particularly

encouraging was the observation of complete responses in patients with

mantle cell lymphoma (MCL) -- a disease that is difficult to treat. In

Europe, Micromet has initiated a phase 2 study in acute lymphoblastic

leukemia, one of the most aggressive blood cancers.

-- Micromet has completed preclinical development for its second BiTE

antibody MT110. MT110 binds to EpCAM, a cell surface molecule that is

highly expressed on many solid tumors and on cancer stem cells -- those

cancer cells responsible for metasta
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... 4 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a ... of cancer and,hepatitis C virus (HCV) infection, today announced ... results ended July 31, 2007 on September,10, 2007, and ... the,results at 11:30 a.m. EDT on the same day. ...
... Sept. 4 Osteotech, Inc.,(Nasdaq: OSTE ), ... repair,of the musculoskeletal system, announced today that Sam ... an overview,of the Company,s strategic direction and market ... Investor Conference. Mr. Owusu-Akyaw is,scheduled to present at ...
... global pharma/biotech industries, Pharmaceutical Manufacturing and Biotechnology Middle East (PABME) 27-29 ... ... Emirates, Sept. 4 The Middle East,market for pharmaceutical manufacturing and biotechnology, ... digits. The market,drivers are: -- Dubai is the commercial, scientific and ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results 2
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/6/2014)... Most cancer deaths occur because of metastasis, yet ... has been slow. , "It,s been particularly challenging ... Taran Gujral, research fellow in systems biology at ... aren,t detected until after they,ve already metastasized." , ... culprit that should help researchers better understand how ...
(Date:11/5/2014)... Janeiro, Brazil -Individuals show great diversity in their ability ... and females greatly differ in their perceptual evaluation of ... smell tests. , Sex differences in olfactory ... and may be connected to one,s perception of smell, ... Thus, women,s olfactory superiority has been suggested to be ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... recently developed mouse model of brain,tumors common in ... human condition and provides unique insight,into tumor development, ... School of Medicine in St. Louis.,After validating their ... blood vessels and immune system cells may be ...
... at the Marine Biological,Laboratory (MBL) has published ... that supports her hypothesis that, when combined, ... as BCE--can act synergistically to alter a ... have previously studied the effects,of these pollutants ...
... crystallized form of a molecular machine that can cut ... for treating diseases such as some forms of cancer ... University researchers froze one of these molecular machines, which ... at mid-point in its work cycle. When frozen, crystallized ...
Cached Biology News:Mouse brain tumors mimic those in human genetic disorder 2Mouse brain tumors mimic those in human genetic disorder 3Clam embryo study shows pollutant mixture adversely affects nerve cell development 2Clam embryo study shows pollutant mixture adversely affects nerve cell development 3Molecular machine may lead to new drugs to combat human diseases 2Molecular machine may lead to new drugs to combat human diseases 3